@article{RichterKruppaMunzetal.2019,
  author    = {Richter, Gesa M. and Kruppa, Jochen and Munz, Matthias and Wiehe, Ricarda and H{\"a}sler, Robert and Franke, Andre and Martins, Orlando and Jockel-Schneider, Yvonne and Bruckmann, Corinna and Dommisch, Henrik and Schaefer, Arne S.},
  title     = {A combined epigenome- and transcriptome-wide association study of the oral masticatory mucosa assigns CYP1B1 a central role for epithelial health in smokers},
  series = {Clinical Epigenetics},
  volume    = {11},
  journal   = {Clinical Epigenetics},
  doi       = {10.1186/s13148-019-0697-y},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-226175},
  pages     = {1-18},
  year      = {2019},
  abstract  = {Background The oral mucosa has an important role in maintaining barrier integrity at the gateway to the gastrointestinal and respiratory tracts. Smoking is a strong environmental risk factor for the common oral inflammatory disease periodontitis and oral cancer. Cigarette smoke affects gene methylation and expression in various tissues. This is the first epigenome-wide association study (EWAS) that aimed to identify biologically active methylation marks of the oral masticatory mucosa that are associated with smoking. Results Ex vivo biopsies of 18 current smokers and 21 never smokers were analysed with the Infinium Methylation EPICBeadChip and combined with whole transcriptome RNA sequencing (RNA-Seq; 16 mio reads per sample) of the same samples. We analysed the associations of CpG methylation values with cigarette smoking and smoke pack year (SPY) levels in an analysis of covariance (ANCOVA). Nine CpGs were significantly associated with smoking status, with three CpGs mapping to the genetic region of CYP1B1 (cytochrome P450 family 1 subfamily B member 1;best p=5.5x10(-8)) and two mapping to AHRR (aryl-hydrocarbon receptor repressor; best p=5.9x10(-9)). In the SPY analysis, 61 CpG sites at 52 loci showed significant associations of the quantity of smoking with changes in methylation values. Here, the most significant association located to the gene CYP1B1, with p=4.0x10(-10). RNA-Seq data showed significantly increased expression of CYP1B1 in smokers compared to non-smokers (p=2.2x10(-14)), together with 13 significantly upregulated transcripts. Six transcripts were significantly downregulated. No differential expression was observed for AHRR. In vitro studies with gingival fibroblasts showed that cigarette smoke extract directly upregulated the expression of CYP1B1. Conclusion This study validated the established role of CYP1B1 and AHRR in xenobiotic metabolism of tobacco smoke and highlights the importance of epigenetic regulation for these genes. For the first time, we give evidence of this role for the oral masticatory mucosa.},
  subject      = {AHRR},
  language  = {en}
}
@article{JockelSchneiderHarksHaubitzetal.2014,
  author    = {Jockel-Schneider, Yvonne and Harks, Inga and Haubitz, Imme and Fickl, Stefan and Eigenthaler, Martin and Schlagenhauf, Ulrich and Baulmann, Johannes},
  title     = {Arterial Stiffness and Pulse Wave Reflection Are Increased in Patients Suffering from Severe Periodontitis},
  series = {PLOS ONE},
  volume    = {9},
  journal   = {PLOS ONE},
  number    = {8},
  issn      = {1932-6203},
  doi       = {10.1371/journalone.0103449},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-119459},
  pages     = {e103449},
  year      = {2014},
  abstract  = {Aim: This single blind cross-sectional study compared the vascular health of subjects suffering from severe chronic periodontitis, severe aggressive periodontitis and periodontal healthy controls by evaluating pulse wave velocity (PWV), augmentation index (AIx) and pulse pressure amplification (PPA). Material and Methods: In a total of 158 subjects, 92 suffering from severe periodontitis and 66 matched periodontal healthy controls, PWV, AIx, central and peripheral blood pressure were recorded using an oscillometric device (Arteriograph). Results: Subjects suffering from severe chronic or aggressive periodontitis exhibited significantly higher PWV (p = 0.00004), higher AIx (p = 0.0049) and lower PPA (p = 0.028) than matched periodontal healthy controls. Conclusions: The results of this study confirm the association between periodontal inflammation and increased cardiovascular risk shown by impaired vascular health in case of severe periodontitis. As impaired vascular health is a common finding in patients suffering from severe periodontal disease a concomitant routine cardiovascular evaluation may be advised.},
  language  = {en}
}
@article{JockelSchneiderStoelzelHessetal.2022,
  author    = {Jockel-Schneider, Yvonne and Stoelzel, Peggy and Hess, Jeanine and Haubitz, Imme and Fickl, Stefan and Schlagenhauf, Ulrich},
  title     = {Impact of a specific collagen peptide food supplement on periodontal inflammation in aftercare patients — a randomised controlled trial},
  series = {Nutrients},
  volume    = {14},
  journal   = {Nutrients},
  number    = {21},
  issn      = {2072-6643},
  doi       = {10.3390/nu14214473},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-290471},
  year      = {2022},
  abstract  = {Background: This controlled clinical trial evaluated the impact of a specific collagen peptide food supplement on parameters of periodontal inflammation in aftercare patients. Methods: A total of 39 study patients were enrolled. At baseline, bleeding on probing (BoP; primary outcome), gingival index (GI), plaque control record (PCR), recession (REC) and probing pocket depth (PPD) for the calculation of the periodontal inflamed surface area (PISA) were documented. After subsequent professional mechanical plaque removal (PMPR), participants were randomly provided with a supply of sachets containing either a specific collagen peptide preparation (test group; n = 20) or a placebo (placebo group; n = 19) to be consumed dissolved in liquid once daily until reevaluation at day 90. Results: PMPR supplemented with the consumption of the specific collagen peptides resulted in a significantly lower mean percentage of persisting BoP-positive sites than PMPR plus placebo (test: 10.4\% baseline vs. 3.0\% reevaluation; placebo: 14.2\% baseline vs. 9.4\% reevaluation; effect size: 0.86). Mean PISA and GI values were also reduced compared to baseline, with a significant difference in favor of the test group (PISA test: 170.6 mm\(^2\) baseline vs. 53.7 mm\(^2\) reevaluation; PISA placebo: 229.4 mm\(^2\) baseline vs. 184.3 mm\(^2\) reevaluation; GI test: 0.5 baseline vs. 0.1 reevaluation; GI placebo: 0.4 baseline vs. 0.3 reevaluation). PCR was also significantly decreased in both experimental groups at revaluation, but the difference between the groups did not reach the level of significance. Conclusions: The supplementary intake of specific collagen peptides may further enhance the anti-inflammatory effect of PMPR in periodontal recall patients.},
  language  = {en}
}
@article{HarksJockelSchneiderSchlagenhaufetal.2016,
  author    = {Harks, Inga and Jockel-Schneider, Yvonne and Schlagenhauf, Ulrich and May, Theodor W. and Gravemeier, Martina and Prior, Karola and Petersilka, Gregor and Ehmke, Gregor},
  title     = {Impact of the Daily Use of a Microcrystal Hydroxyapatite Dentifrice on De Novo Plaque Formation and Clinical/Microbiological Parameters of Periodontal Health. A Randomized Trial},
  series = {PLoS ONE},
  volume    = {11},
  journal   = {PLoS ONE},
  number    = {7},
  doi       = {10.1371/journal.pone.0160142},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-166853},
  pages     = {e0160142},
  year      = {2016},
  abstract  = {Aim This 12-week prospective, randomized, double-blind, two-center trial evaluated the impact of a microcrystalline zinc hydroxyapatite (mHA) dentifrice on plaque formation rate (PFR) in chronic periodontitis patients. We hypothesized that mHA precipitates cause delayed plaque development when compared to a fluoridated control (AmF/SnF\(_{2}\)), and therefore would improve periodontal health. Material \& Methods At baseline and after 4 and 12 weeks, PFR and other clinical and microbiological parameters were recorded. Seventy periodontitis patients received a mHA or AmF/SnF\(_{2}\) dentifrice as daily oral care without hygiene instructions. Four weeks after baseline, participants received full mouth debridement and continued using the dentifrices for another 8 weeks. Results Primary outcome PFR did not change statistically significantly from baseline to weeks 4 and 12, neither in mHA (n = 33; 51.7±17.2\% vs. 48.5±16.65\% vs. 48.4±19.9\%) nor in AmF/SnF2-group (n = 34; 52.3±17.5\% vs. 52.5±21.3\% vs. 46.1±21.8\%). Secondary clinical parameters such as plaque control record, gingival index, bleeding on probing, and pocket probing depth improved, but between-group differences were not statistically significant. Microbiological analyses showed similar slight decreases in colony-forming units in both groups. Conclusion In patients with mild-to-moderate periodontitis, periodontal therapy and use of a mHA-or AmF/SnF\(_{2}\) dentifrice without instructions induced comparable improvements in periodontal health but did not significantly reduce the PFR.},
  language  = {en}
}
@article{SchlagenhaufJakobEigenthaleretal.2016,
  author    = {Schlagenhauf, Ulrich and Jakob, Lena and Eigenthaler, Martin and Segerer, Sabine and Jockel-Schneider, Yvonne and Rehn, Monika},
  title     = {Regular consumption of Lactobacillus reuteri-containing lozenges reduces pregnancy gingivitis: an RCT},
  series = {Journal of Clinical Periodontology},
  volume    = {43},
  journal   = {Journal of Clinical Periodontology},
  number    = {11},
  doi       = {10.1111/jcpe.12606},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-186783},
  pages     = {948-954},
  year      = {2016},
  abstract  = {Aim: This randomized controlled trial assessed the impact of Lactobacillus reuteri on pregnancy gingivitis in healthy women. Materials and Methods: Forty-five healthy women (24 test/21 placebo) with pregnancy gingivitis in the third trimester of pregnancy were enrolled. At baseline Gingival Index (GI) and Plaque Index (PlI) were assessed at the Ramfjord teeth and venous blood taken for TNF-alpha analysis. Subsequently participants were randomly provided with lozenges to be consumed 2 9 daily until birth (approx. 7 weeks) containing >= 10(8) CFU L. reuteri ATCC PTA 5289 and >= 10(8) CFU L. reuteri DSM 17938 (test) or being devoid of L. reuteri (placebo). Within 2 days after birth recording of GI, PlI and blood sampling were repeated. Results: At baseline, mean GI and mean PlI did not differ significantly between both groups. In the test group mean TNF-alpha serum level was significantly (p < 0.02) lower than in the placebo group. At reevaluation, mean GI and mean PlI of the test group were both significantly (p < 0.0001) lower than in the placebo group. Mean TNF-alpha serum level did no longer differ significantly between the groups. Conclusions: The consumption of L. reuteri lozenges may be a useful adjunct in the control of pregnancy gingivitis.},
  language  = {en}
}